Niacin's effect on cardiovascular risk: have we finally learned our lesson?
South Australian Health and Medical Research Institute, University of Adelaide, Australia.
Stephen J
SJ
Nicholls
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D050197:Atherosclerosis / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced*; D009525:Niacin / Q000008:administration & dosage* / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007211:Indoles; D009525:Niacin